Health
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies
About this update from Uniqure N.v.
[{"type":"image","alt":"uniQure Inc.","displaySize":"","headline":null,"caption":"uniQure Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/cb8da6eec71588a1000495a1c5d28a54"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MCbXlQWdgvZoIruFbz16Zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cb8da6eec71588a1000495a1c5d28a54","width":300,"height":96}},"lazy":false},{"type":"text","content":"~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~","length":130,"tagName":"p"},{"type":"text","content":"~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~","length":117,"tagName":"p"},{"type":"text","content":"~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~","length":90,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase I/IIa trial of AMT-191, an investigational AAV gene therapy for the treatment of Fabry disease. The updated data was presented at the WORLDSymposium in San Diego, California.","length":478,"tagName":"p"},{"type":"text","content":"As of the January 8, 2026 study data cutoff date, all 11 patients in the three dose cohorts (6x1013 genome copies/kilogram (gc/kg), 4x1013 gc/kg and 2x1013 gc/kg) had elevated α-galactosidase A (α-Gal A) activity.","length":213,"tagName":"p"},{"type":"text","content":"Importantly, dose-dependent elevations were observed across the three dose levels with α-Gal A activity ranging from 0.34- to 82.2-fold above mean normal level1 at the lowest dose, 1.6- to 312.52-fold at the mid dose, and 27.7- to 223.7-fold at the highest dose. These increases were durable for the measured time period ranging from the longest follow-up period of more than a year in a treated patient (high-dose cohort) to the shortest follow-up period of four months in a treated patient (mid-dose cohort).","length":510,"tagName":"p"},{"type":"...